0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Hepatotoxicity in Cholangiography

Francis J. Scholz, MD; David O. Johnston, MD; Robert E. Wise, MD
JAMA. 1974;229(13):1724. doi:10.1001/jama.1974.03230510016012.
Text Size: A A A
Published online

To the Editor.—  In regard to the report of a hepatotoxic reaction (228:1420, 1974), we recently presented at the annual meeting of the Radiologic Society of North America the results of a comparison study of differing dosage regimens in intravenous cholangiography.One interesting finding was elevation of the serum glutamic oxaloacetic transaminase (SGOT) level after cholangiography. Of 149 patients who received the single dose recommended by the manufacturer, 13 (8.7%) developed an elevated SGOT level. Of 126 patients who received the double dose advocated recently in the literature,1-3 23 (18.3%) developed abnormal SGOT levels after cholangiography. A 77% incidence in elevated SGOT levels is mentioned in the German literature when a double dose of a mixture of ioglycamate meglumine and ioglycamate sodium (Bilivistan) was used for cholangiography.4 Other German authors have also noted elevations of SGOT values when doses of this mixture or iodipamide meglumine injection (Biligrafin) larger

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();